Obel A O
Department of Medicine, College of Health Sciences, University of Nairobi, Kenya.
J Cardiovasc Pharmacol. 1989 Aug;14(2):294-6. doi: 10.1097/00005344-198908000-00016.
Forty-eight black patients with mildly increased blood pressure (BP) that had not yet been subjected to treatment took part in a double-blind clinical trial of the efficacy and tolerability of oral potassium supplements (64 mmol daily) versus a matching placebo (made of starch with coating) in a 16-week study. Potassium supplements produced a significant decrease in mean supine and standing BP within 4 weeks after treatment inception. Urinary potassium excretion increased significantly in the 24 patients who received potassium supplements (p less than 0.001). No significant changes occurred in plasma sodium and potassium concentrations or in urinary excretion of sodium during the study. All patients completed the trial without experiencing any notable untoward effects. These results are consistent with the premise that oral potassium supplements may exert hypotensive effects of clinically significant degree in patients with mild hypertension.
48名血压轻度升高且尚未接受治疗的黑人患者参与了一项为期16周的双盲临床试验，该试验比较了口服钾补充剂（每日64 mmol）与匹配安慰剂（由带包衣的淀粉制成）的疗效和耐受性。在开始治疗后的4周内，钾补充剂使平均仰卧位和站立位血压显著降低。接受钾补充剂的24名患者的尿钾排泄显著增加（p小于0.001）。在研究期间，血浆钠和钾浓度以及尿钠排泄均未发生显著变化。所有患者均完成了试验，未出现任何明显的不良影响。这些结果与以下前提一致，即口服钾补充剂可能对轻度高血压患者产生具有临床显著程度的降压作用。
